Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844211 | 0.91 | KCNH2 (0.58) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL15569388 | 0.88 | MAPT (0.62) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL12847056 | 0.87 | KCNH2 (0.55) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL9912397 | 0.85 | TP53 (0.50) | LTA4HMAPTALDH1A1THRBSMN1; SMN2 | |
| SCHEMBL4172495 | 0.85 | MAPT (0.58) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL5071255 | 0.83 | MAPT (0.57) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL15956633 | 0.83 | MAPT (0.57) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL12788366 | 0.83 | KCNH2 (0.52) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL30924929 | 0.82 | MAPT (0.55) | KCNH2LTA4HMAPTLMNAALDH1A1 | |
| SCHEMBL853489 | 0.82 | MAPT (0.55) | KCNH2LTA4HMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119053610-A | 1,3,4, 7-Tetrahydro-2H-pyrrolo [3',2':5,6] pyrido [2,3-b ] [1,4] oxazepine Bcl-2 inhibitors | 艾伯维公司 | 2024-11-29 | — | — | CN | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023141536-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS | ABBVIE INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| EP-1423383-B1 | PYRIDINE SUBSTITUTED FURAN DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-06 | — | — | EP | disclosed |
| US-7375105-B2 | Pyridine substituted furan derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-05-20 | — | — | US | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| EP-1318992-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003022838-A1 | PYRIDINE SUBSTITUTED FURAN DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-20 | — | — | WO | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| WO-2002024680-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0874809-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997025309-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | KCNH2 53/4885LTA4H 2258/4885MAPT 4241/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | KCNH2 330/4885LTA4H 204/4885MAPT 4485/4885 |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | BCL9L, BCL2L1, BCL2L2 | KCNH2 330/4885LTA4H 204/4885MAPT 4485/4885 |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | BCL9L, BCL2L1, BCL9 | KCNH2 322/4885LTA4H 195/4885MAPT 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.